Standard Treatment Plan for Breast Cancer
Breast cancer treatment follows a multimodal approach combining surgery, radiation, systemic therapy (chemotherapy, hormonal therapy, and/or targeted therapy), with specific treatment determined by stage, hormone receptor status, HER2 status, and menopausal status.
Treatment Framework by Stage
Early Stage Disease (Stage 0-III)
Local Treatment
Surgery is the cornerstone of early-stage breast cancer treatment, with two equivalent options for survival 1:
- Breast-conserving surgery (lumpectomy) + radiation therapy (50 Gy in 25 fractions minimum) - preferred when complete excision with good cosmetic results is achievable 1
- Mastectomy (with or without reconstruction) - indicated when breast conservation is not feasible 1
Critical surgical considerations:
- Women under 50 years require a radiation boost to the tumor bed even with clear margins 1
- After mastectomy, chest wall radiotherapy is indicated for patients with high-risk factors 1
- Sentinel lymph node biopsy for axillary staging 2
- Irradiation of internal mammary and supraclavicular lymph nodes is indicated with axillary node involvement 1
Systemic Adjuvant Therapy
Treatment selection is algorithmically determined by:
1. Hormone Receptor Status:
ER/PR-positive tumors:
- Tamoxifen 20 mg daily for 5 years is standard for all ages if hormone receptors are present 1
- Postmenopausal women with node-positive disease: Tamoxifen alone or combined with chemotherapy 1
- Premenopausal women with node-positive disease: Chemotherapy plus tamoxifen 1
- Never prescribe tamoxifen for ER-negative tumors 1
ER/PR-negative tumors:
- Chemotherapy without hormonal therapy 1
2. Chemotherapy Regimens:
Anthracycline-containing polychemotherapy is superior to CMF (cyclophosphamide, methotrexate, fluorouracil) and is the current standard 1:
- Doxorubicin/cyclophosphamide or epirubicin/cyclophosphamide
- Fluorouracil/doxorubicin/cyclophosphamide
- Fluorouracil/epirubicin/cyclophosphamide
- 4-6 cycles administered every 3-4 weeks 1
Indications:
- Node-positive disease (all patients benefit) 1
- Selected node-negative patients with high-risk features 1
- Premenopausal women benefit more than postmenopausal women 1
3. HER2-Positive Disease:
- Trastuzumab with or without non-anthracycline chemotherapy for HER2-positive tumors (confirmed by FISH or CISH) 3, 4
- Cardiac monitoring required before and during trastuzumab therapy 3
Neoadjuvant (Preoperative) Therapy
Neoadjuvant chemotherapy is an option when breast-conserving surgery is initially not possible but the patient desires breast conservation 1, 5, 1:
- Avoids mastectomy in >50% of women 1
- Does not affect survival compared to adjuvant therapy 1
- Higher local recurrence risk than primary mastectomy 1
- After neoadjuvant therapy, perform locoregional treatment as if it were first-line 1
Metastatic Disease (Stage IV)
Treatment is palliative, not curative, focusing on quality of life and symptom control 3:
Hormone Receptor-Positive Metastatic Disease:
First-line endocrine therapy is preferred for patients without visceral crisis 3:
- Options include: anastrozole, letrozole, exemestane, fulvestrant, megestrol acetate 3
- Long disease-free interval (>1-2 years), limited metastatic sites, and no visceral involvement favor endocrine therapy 3
Chemotherapy is indicated when:
- Evidence of endocrine resistance 3
- Visceral crisis or life-threatening disease 3
- Never use concomitant chemohormonal therapy 3
Chemotherapy Regimens for Metastatic Disease:
No single regimen is superior; selection based on prior treatments, performance status, and disease extent 3:
- Non-anthracycline: Capecitabine, vinorelbine, cyclophosphamide/methotrexate/fluorouracil 3
- Anthracycline-containing: Doxorubicin/cyclophosphamide, liposomal doxorubicin 3
- Taxane-containing: Paclitaxel or docetaxel (weekly or three-weekly), docetaxel/capecitabine 3
Treatment duration: Continue until progression or unacceptable toxicity; prolonged treatment may improve quality of life and time to progression but no survival advantage 3
HER2-Positive Metastatic Disease:
Trastuzumab with or without non-anthracycline chemotherapy 3
- Cardiac monitoring mandatory 3
Special Populations
Elderly Patients:
- Use full-dose standard regimens when feasible 4
- Geriatric assessment (G8 screening tool) before treatment decisions 4
- Single-agent capecitabine or docetaxel is inferior to standard multidrug regimens 4
Male Breast Cancer:
- Tamoxifen is the standard adjuvant endocrine therapy 4
- Aromatase inhibitors alone should not be used (lower efficacy) 4
- Chemotherapy and anti-HER2 therapy follow same recommendations as female patients 4
DCIS (Stage 0):
- Lumpectomy + radiation or mastectomy 6
- Tamoxifen or aromatase inhibitors for ER-positive DCIS to reduce recurrence risk 4
Critical Pitfalls to Avoid
- Never omit radiation after breast-conserving surgery - significantly reduces local recurrence 1
- Never use tamoxifen for ER-negative tumors 1
- Never irradiate the axilla after axillary dissection - increases complications 1
- Never delay chemotherapy - should start promptly 1
- Never use high-dose chemotherapy with stem cell support - no evidence of benefit 3, 1